SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high244.75 17/10/17
52 week low71.90 03/05/17
52 week change 119.75 (100.42%)
4 week volume12,624,585 22/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 9815T Silence Therapeutics PLC 18 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Thera...

Silence Therapeutics granted US patents

Silence Therapeutics said the US Patent and Trade Mark Office yesterday granted it with two new patents. US patent appli...

Further US patents granted

RNS Number: 8740T Silence Therapeutics PLC 18 October 2017 Further US patents granted 18 October 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Offi...

Serving of claim in the UK High Court

RNS Number: 8535T Silence Therapeutics PLC 17 October 2017 Serving of claim in the UK High Court 17 October 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has today delivered to...

Silence Therapeutics appoints new chairman

Silence Therapeutics has appointed Annalisa Jenkins as its new chairman, with immediate effect. Outgoing chairman Steph...

Appointment of Non-Executive Chair

RNS Number: 6230T Silence Therapeutics PLC 16 October 2017 Appointment of Dr. Annalisa Jenkins, MBBS, FRCP as Non-Executive Chair 16 th October 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, ...

Silence Therapeutics granted US patent

Silence Therapeutics said it has been granted a key patent in the US for its RNA-based treatments for serious diseases. The ...

Key US patent granted

RNS Number: 2482T Silence Therapeutics PLC 11 October 2017 Key US patent granted 11 October 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Office ye...

Fundamental DataMore

EPS-12.1
Dividend yield0 %

Latest discussion posts More

  • Re: Slow decline.

    Hi, Totally agree and I am not sure why apart from just general lack of interest. The attached might help cheer you up a ...
    27-Apr-2017
    tallyfox
  • Slow decline.

    Feels like death by a thousand cuts at the moment. What's it going to take to reverse this decline?
    27-Apr-2017
    rikid

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.34%
BP24%
TESCO19%
BARCLAYS19%
ROYAL BANK SCOT19%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN